The AIDS drug, PrEP will be available in generic form in 2020, a year before the patent wears off.
Bartender Alexandria Ocasio-Cortez is taking credit for the deal that was worked out between Gilead and Teva Pharmaceutical that allows Teva to produce a generic version of Truvada beginning in 2020.
The only problem for AOC is that the agreement was made n 2014 and she did not become a member of congress until 2019.
In my first 11 months I’ve cosponsored 339 pieces of legislation, authored 15, took on Big Pharma w/ my colleagues in hearings that brought PreP generic a year early & exposed abuse of power.
In 4 years, you’ve jailed kids & made corruption the cause celebré.
Try to keep up. https://t.co/lyg30LKVCd
— Alexandria Ocasio-Cortez (@AOC) November 24, 2019
What’s next? Will she take credit for writing the bill of rights or founding Plymouth colony? Since taking office, AOC has come up with some of the most ridiculous statements we have ever heard.
This is just one more in a long line of them. Who has more provable crimes? President Trump or The Squad? The numbers are not even close.
Gilead that makes PrEP , a drug that can stop the transmission of HIV by up to 99% made the deal with Teva in 2014 and the deal was announced publicly weeks before the Democrats met to discuss fast tracking the drug.
Join us again next week when AOC announces how she ended slavery and fought against dinosaur farts that caused global warming at the end of the ICE Age.
Gilead’s patent for an active ingredient in Truvada—the company’s HIV prevention drug—will expire in 2021, but currently prohibits most competitors from making generic versions of the medicine.
However, a 2014 legal settlement between Gilead and Teva Pharmaceutical authorized the latter to sell generic Truvada starting in 2020, a year before the patent is set to expire.
In May, Gilead representative Douglas Brooks said the agreement was “not related to current discussions with the U.S. government” to broaden access to the medicine, denying the possibility that politicians such as Ocasio-Cortez had any bearing on the decision to allow early manufacturing of the generic drug.
Ocasio-Cortez’s Democratic colleagues were aware of the 2014 legal settlement, which was reported by media outlets and included in O’Day’s written testimony to Congress.
Rep. John Sarbanes (D., Md.) explicitly referred to the settlement during the mid-May hearing, which Ocasio-Cortez attended, saying that “Gilead allowed Teva to come to the market in 2020” due to the settlement.